Author Title Type [ Year(Asc)]
Filters: Author is Shpall, Elizabeth J  [Clear All Filters]
Heslop, H.E., and Shpall, E.J. (2019). HARMONIZING IMMUNE EFFECTOR TOXICITY REPORTING.Biol Blood Marrow Transplant.
Saini, N.Y., Saliba, R.M., Rondon, G., Maadani, F., Popat, U., Hosing, C.M., Betul, O., Bashir, Q., Olson, A., Nieto, Y., et al. (2019). Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma.Biol Blood Marrow Transplant.
Srinivasan, V.M., Gumin, J., Camstra, K.M., Chen, S.R., Johnson, J.N., Shimizu, Y., Kerrigan, B.C.Parker, Shpall, E.J., Lang, F.F., and Kan, P. (2019). Microcatheter delivery of neurotherapeutics: compatibility with mesenchymal stem cells.J Neurosurg1-9.
Kongtim, P., Hasan, O., Perez, J.Miguel Ram, Varma, A., Wang, S.A., Patel, K.P., Chen, J., Rondon, G., Srour, S., Bashir, Q., et al. (2019). A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.
Li, L., Chen, H., Marin, D., Xi, Y., Miao, Q., Lv, J., Banerjee, P.Prosad, Shaim, H., Daher, M., Basar, R., et al. (2019). A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation.Blood Adv3, 4117-4130.
Varma, A., Sui, D., Milton, D.R., Tang, G., Saini, N., Hasan, O., Mukherjee, A., Joseph, J.Joy, Bashir, Q., Rondon, G., et al. (2019). Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT.Biol Blood Marrow Transplant.
Langman, L.J., Nesher, L., Shah, D.P., Azzi, J.M., Shpall, E.J., Rezvani, K., Black, J.L., and Chemaly, R.F. (2016). Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients.J Mol Diagn.
Nieto, Y., Valdez, B.C., Thall, P.F., Jones, R.B., Wei, W., Myers, A., Hosing, C., Ahmed, S., Popat, U., Shpall, E.J., et al. (2016). Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.Cancer.
Ma, Q., Garber, H.R., Lu, S., He, H., Tallis, E., Ding, X., Sergeeva, A., Wood, M.S., Dotti, G., Salvado, B., et al. (2016). A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.Cytotherapy.
Kebriaei, P., Singh, H., M Huls, H., Figliola, M.J., Bassett, R., Olivares, S., Jena, B., Dawson, M.J., Kumaresan, P.R., Su, S., et al. (2016). Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest.
Aung, F.M., Lichtiger, B., Rondon, G., C Yin, C., Alousi, A., Ahmed, S., Andersson, B., Bashier, Q., Ciurea, S.O., Hosing, C., et al. (2016). Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.Biol Blood Marrow Transplant.
Gaballa, S., Ge, I., Fakih, R.El, Brammer, J.E., Kongtim, P., Tomuleasa, C., Wang, S.A., Lee, D., Petropoulos, D., Cao, K., et al. (2016). Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer.
Shah, N., Martin-Antonio, B., Yang, H., Ku, S., Lee, D.A., Cooper, L.J.N., Decker, W.K., Li, S., Robinson, S.N., Sekine, T., et al. (2013). Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.Plos One8, e76781.
Hart, J.W., Shiue, L.H., Shpall, E.J., and Alousi, A.M. (2013). Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.Ther Adv Hematol4, 320-334.
Bayraktar, U.D., Shpall, E.J., Liu, P., Ciurea, S.O., Rondon, G., de Lima, M., Cardenas-Turanzas, M., Price, K.J., Champlin, R.E., and Nates, J.L. (2013). Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit.J Clin Oncol.
Russell Y Cruz, C., Micklethwaite, K.P., Savoldo, B., Ramos, C.A., Lam, S., Ku, S., Diouf, O., Liu, E., A Barrett, J., Ito, S., et al. (2013). Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study.Blood.
Leen, A.M., Bollard, C.M., Mendizabal, A.M., Shpall, E.J., Szabolcs, P., Antin, J.H., Kapoor, N., Pai, S.-Y., Rowley, S.D., Kebriaei, P., et al. (2013). Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation.Blood.